According to the new market research report RSV Diagnostics Market is expected to reach USD 929.2 Million by 2022 from USD 574.3 Million in 2017, at a CAGR of 10.1%.
Factors driving the growth of this market include rising burden of RSV infections, growing demand for PoC molecular diagnostic tests for the diagnosis of RSV infections, and increasing approval of RSV diagnostic kits and assays.
Download PDF Brochure: www.marketsandmarkets.com/pdfdownloadNew.asp?id=95683942
Based on method, the market is segmented into molecular diagnostics, rapid antigen detection tests, and other methods. The molecular diagnostics segment is estimated to register the highest growth during the forecast period.
On the basis of products, the Respiratory Syncytial Virus Diagnostics Market is categorized into kits and assays, instruments, and other products. The kits and assays segment is expected to register the highest growth during the forecast period.
Based on end user, the RSV Diagnostics Market is segmented into hospitals & clinics and home care. The hospitals and clinics segment is estimated to grow at the highest rate during the forecast period. The increasing demand for RSV diagnostic testing in hospitals and clinics is driving the growth of this segment.
Based on region, the Respiratory Syncytial Virus Diagnostics Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is estimated to dominate the RSV diagnostics market in 2017. This is mainly due to factors such as the increasing patient base of RSV diseases, technological advancements in PoC molecular diagnostic devices, and growing healthcare expenditures.
Request For Sample Pages: www.marketsandmarkets.com/requestsampleNew.asp?id=95683942
Key players in the RSV diagnostics market include bioMérieux (France), Becton Dickinson (US), Abbott (US), Roche (Switzerland), Danaher (US), Luminex (US), BioCartis (Belgium), Hologic (US), and Fast Track Diagnostics (Luxembourg).
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062